Log in

NASDAQ:RYTMRhythm Pharmaceuticals News Headlines

$19.84
-0.31 (-1.54 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$19.77
Now: $19.84
$20.41
50-Day Range
$15.31
MA: $18.72
$20.40
52-Week Range
$12.99
Now: $19.84
$26.11
Volume108,344 shs
Average Volume169,611 shs
Market Capitalization$874.75 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94

Headlines

Rhythm Pharmaceuticals (NASDAQ RYTM) News Headlines

Source:
DateHeadline
Todd Foley Sells 19,152 Shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) StockTodd Foley Sells 19,152 Shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Stock
www.americanbankingnews.com - May 28 at 8:50 PM
Todd Foley Sells 25,594 Shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) StockTodd Foley Sells 25,594 Shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Stock
www.americanbankingnews.com - May 26 at 11:04 PM
Insider Selling: Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Director Sells 44,421 Shares of StockInsider Selling: Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Director Sells 44,421 Shares of Stock
www.americanbankingnews.com - May 26 at 10:32 PM
Rhythm Pharmaceuticals to Present Virtually at Upcoming Investor Conference in JuneRhythm Pharmaceuticals to Present Virtually at Upcoming Investor Conference in June
finance.yahoo.com - May 26 at 12:53 PM
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Short Interest Down 16.3% in MayRhythm Pharmaceuticals Inc (NASDAQ:RYTM) Short Interest Down 16.3% in May
www.americanbankingnews.com - May 19 at 1:12 PM
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Director Todd Foley Sells 1,837 SharesRhythm Pharmaceuticals Inc (NASDAQ:RYTM) Director Todd Foley Sells 1,837 Shares
www.americanbankingnews.com - May 15 at 6:48 PM
Short Interest in Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Drops By 12.2%Short Interest in Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Drops By 12.2%
www.americanbankingnews.com - May 13 at 9:36 PM
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Given Average Recommendation of "Buy" by BrokeragesRhythm Pharmaceuticals Inc (NASDAQ:RYTM) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 13 at 2:39 AM
Insider Selling: Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Director Sells 6,633 Shares of StockInsider Selling: Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Director Sells 6,633 Shares of Stock
www.americanbankingnews.com - May 12 at 6:20 PM
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Director Sells $450,632.70 in StockRhythm Pharmaceuticals Inc (NASDAQ:RYTM) Director Sells $450,632.70 in Stock
www.americanbankingnews.com - May 12 at 5:46 PM
Sales of Cardiac Rhythm Management Market to Decelerate in 2020 as COVID-19 Pandemic Takes its Toll on Global MarketSales of Cardiac Rhythm Management Market to Decelerate in 2020 as COVID-19 Pandemic Takes its Toll on Global Market
www.marketwatch.com - May 12 at 2:24 AM
-$0.84 EPS Expected for Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) This Quarter-$0.84 EPS Expected for Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) This Quarter
www.americanbankingnews.com - May 9 at 6:25 AM
Todd Foley Sells 1,626 Shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) StockTodd Foley Sells 1,626 Shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Stock
www.americanbankingnews.com - May 7 at 7:10 PM
Rhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly  Earnings Results, Beats Expectations By $0.04 EPSRhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - May 5 at 8:46 AM
Rhythm Pharmaceuticals to Present Virtually at 2020 BofA Securities Health Care ConferenceRhythm Pharmaceuticals to Present Virtually at 2020 BofA Securities Health Care Conference
finance.yahoo.com - May 5 at 8:33 AM
Stifel Nicolaus Reaffirms "Buy" Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM)Stifel Nicolaus Reaffirms "Buy" Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM)
www.americanbankingnews.com - May 5 at 7:09 AM
Needham & Company LLC Reiterates Buy Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM)Needham & Company LLC Reiterates Buy Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM)
www.americanbankingnews.com - May 4 at 5:35 PM
Rhythm Pharmaceuticals EPS beats by $0.02Rhythm Pharmaceuticals EPS beats by $0.02
seekingalpha.com - May 4 at 5:31 PM
Rhythm Pharmaceuticals Reports First Quarter 2020 Financial ResultsRhythm Pharmaceuticals Reports First Quarter 2020 Financial Results
finance.yahoo.com - May 4 at 5:31 PM
We're Not Very Worried About Rhythm Pharmaceuticals's (NASDAQ:RYTM) Cash Burn RateWe're Not Very Worried About Rhythm Pharmaceuticals's (NASDAQ:RYTM) Cash Burn Rate
finance.yahoo.com - April 21 at 1:39 PM
Meet the Apple of Our Eye: Raghu Ram Shares First Pics of Son RhythmMeet the Apple of Our Eye: Raghu Ram Shares First Pics of Son Rhythm
www.msn.com - April 21 at 8:38 AM
Rhythm Pharmaceuticals to Present Virtually at Needham & Co. 19th Annual Healthcare ConferenceRhythm Pharmaceuticals to Present Virtually at Needham & Co. 19th Annual Healthcare Conference
finance.yahoo.com - April 7 at 5:18 PM
Worldwide Cardiac Monitoring & Cardiac Rhythm Management Devices Market (2019 to 2023) - Forecast and Analysis - ResearchAndMarkets.comWorldwide Cardiac Monitoring & Cardiac Rhythm Management Devices Market (2019 to 2023) - Forecast and Analysis - ResearchAndMarkets.com
www.businesswire.com - April 2 at 5:04 PM
Cardiac Rhythm Management Market Opportunities And Forecast Assessment, 2025Cardiac Rhythm Management Market Opportunities And Forecast Assessment, 2025
www.marketwatch.com - April 1 at 3:43 PM
Rhythm Pharma completes U.S. setmelanotide applicationRhythm Pharma completes U.S. setmelanotide application
seekingalpha.com - March 30 at 5:59 PM
Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency ObesitiesRhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities
finance.yahoo.com - March 30 at 8:15 AM
Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business OperationsRhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations
finance.yahoo.com - March 30 at 8:15 AM
Cardiac Rhythm Management Devices Market Key Vendors, Topographical Regions, and Industry Segmentation 2026Cardiac Rhythm Management Devices Market Key Vendors, Topographical Regions, and Industry Segmentation 2026
www.marketwatch.com - March 26 at 6:57 AM
Cardiac Rhythm Management Devices Market To Grow At 6.96% CAGR Between 2018 - 2026 analysis by Credence ResearchCardiac Rhythm Management Devices Market To Grow At 6.96% CAGR Between 2018 - 2026 analysis by Credence Research
www.marketwatch.com - March 25 at 8:38 AM
T.I. announces Netflixs Rhythm & Flow will be back for season 2T.I. announces Netflix's Rhythm & Flow will be back for season 2
www.msn.com - March 24 at 6:59 PM
Cardiac Monitoring and Cardiac Rhythm Market By Manufacturers, Regions, Type, Application, Forecast 2020-2026Cardiac Monitoring and Cardiac Rhythm Market By Manufacturers, Regions, Type, Application, Forecast 2020-2026
www.marketwatch.com - March 24 at 8:59 AM
Cardiac Rhythm Management Devices Market Worldwide Growth, Segmentation, Industry Growth, Trends Forecast to 2026Cardiac Rhythm Management Devices Market Worldwide Growth, Segmentation, Industry Growth, Trends Forecast to 2026
www.marketwatch.com - March 23 at 9:04 AM
Cardiac Monitoring and Cardiac Rhythm Management Market 2020 Global Analysis, Opportunities And Forecast To 2025Cardiac Monitoring and Cardiac Rhythm Management Market 2020 Global Analysis, Opportunities And Forecast To 2025
www.marketwatch.com - March 19 at 7:28 AM
Insights into the Worldwide Cardiac Rhythm Management Market to 2025 - ResearchAndMarkets.comInsights into the Worldwide Cardiac Rhythm Management Market to 2025 - ResearchAndMarkets.com
www.businesswire.com - March 18 at 8:23 AM
Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström SyndromeRhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome
finance.yahoo.com - March 18 at 8:23 AM
Cardiac Monitoring and Cardiac Rhythm Market Incredible Possibilities, Growth with Industry Study, Detailed Analysis and Forecast to 2026Cardiac Monitoring and Cardiac Rhythm Market Incredible Possibilities, Growth with Industry Study, Detailed Analysis and Forecast to 2026
www.marketwatch.com - March 11 at 8:15 AM
Rhythm Pharmaceuticals EPS beats by $0.10Rhythm Pharmaceuticals EPS beats by $0.10
seekingalpha.com - March 2 at 9:24 AM
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial ResultsRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
finance.yahoo.com - March 2 at 9:24 AM
Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care ConferenceRhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference
finance.yahoo.com - February 25 at 12:49 PM
Cardiac Rhythm Management Market Research Report 2019-2025: By Product, Application, Manufacturer, Sales and SegmentationCardiac Rhythm Management Market Research Report 2019-2025: By Product, Application, Manufacturer, Sales and Segmentation
www.marketwatch.com - January 18 at 12:33 PM
Rhythm Pharmaceuticals stock falls on news CEO is leavingRhythm Pharmaceuticals stock falls on news CEO is leaving
finance.yahoo.com - January 7 at 4:41 PM
BRIEF-Rhythm Pharma Says Keith Gottesdiener To Step Down As CEOBRIEF-Rhythm Pharma Says Keith Gottesdiener To Step Down As CEO
www.msn.com - January 7 at 2:25 AM
Rhythm Pharma CEO to step downRhythm Pharma CEO to step down
seekingalpha.com - January 6 at 9:24 PM
Rhythm Pharmaceuticals Announces Leadership TransitionRhythm Pharmaceuticals Announces Leadership Transition
finance.yahoo.com - January 6 at 4:23 PM
Hedge Funds Are Dumping Rhythm Pharmaceuticals, Inc. (RYTM)Hedge Funds Are Dumping Rhythm Pharmaceuticals, Inc. (RYTM)
finance.yahoo.com - December 17 at 8:32 PM
Rhythm Pharma (+4%) completes enrollment in setmelanotide obesity studyRhythm Pharma (+4%) completes enrollment in setmelanotide obesity study
seekingalpha.com - December 5 at 1:46 PM
Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström SyndromesRhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
finance.yahoo.com - December 5 at 8:46 AM
Rhythm Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?Rhythm Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - November 22 at 11:18 AM
Rhythm Pharmaceuticals to Present at Stifel 2019 Healthcare ConferenceRhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference
www.globenewswire.com - November 13 at 8:02 AM
Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019
finance.yahoo.com - November 4 at 7:26 PM
This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.